Incyte Corp. (INCY) and Biogen Inc. (BIIB) are experiencing notable stock gains, with Incyte's Q2 earnings exceeding expectations and management raising full-year sales guidance to between $5.13 billion and $5.26 billion.
Incyte's flagship drug, Jakafi, continues to perform well, while new products are contributing to growth, with total revenue reported at $1.67 billion and adjusted EPS at $3.09, far surpassing the consensus estimate of $2.12. The stock reached a 52-week high of $132, indicating strong market demand.
Biogen, valued at $30 billion, reported Q2 revenue of $2.74 billion, beating estimates by $240 million, with adjusted EPS of $3.60, 18% above consensus. The company is also focusing on growth through acquisitions, including a recent purchase of Apellis, which is expected to enhance earnings in the future. Biogen's stock is currently in a consolidation phase, with a key resistance level at $218.
Both companies are positioned for potential further growth, making them attractive options for investors looking at the biotech sector